Division of Nephrology, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA , USA.
Department of Pediatrics, Center for Pediatric Nephrology, Cleveland Clinic Children's, Case Western Reserve University , Cleveland, OH , USA.
Front Pediatr. 2016 Aug 10;4:82. doi: 10.3389/fped.2016.00082. eCollection 2016.
Previous studies have suggested that some children with autosomal recessive polycystic kidney disease (ARPKD) have growth impairment out of proportion to their degree of chronic kidney disease (CKD). The objective of this study was to systematically compare growth parameters in children with ARPKD to those with other congenital causes of CKD in the chronic kidney disease in Children (CKiD) prospective cohort study.
Height SD scores (z-scores), proportion of children with severe short stature (z-score < -1.88), rates of growth hormone use, and annual change in height z-score were analyzed in children with ARPKD (n = 22) compared with two matched control groups: children with aplastic/hypoplastic/dysplastic kidneys (n = 44) and obstructive uropathy (OU) (n = 44). Differences in baseline characteristics were tested by Wilcoxon rank-sum test or Fisher's exact test. Matched differences in annual change in height z-score were tested by Wilcoxon signed-rank test.
Median height z-score in children with ARPKD was -1.1 [interquartile range -1.5, -0.2]; 14% of the ARPKD group had height z-score < -1.88, and 18% were using growth hormone. There were no significant differences in median height z-score, proportion with height z-score < -1.88, growth hormone use, or annual change in height z-score between the ARPKD and control groups.
Children with ARPKD and mild-to-moderate CKD in the CKiD cohort have a high prevalence of growth abnormalities, but these are similar to children with other congenital causes of CKD. This study does not support a disease-specific effect of ARPKD on growth, at least in the subset of children with mild-to-moderate CKD.
先前的研究表明,一些常染色体隐性多囊肾病 (ARPKD) 患儿的生长障碍与其慢性肾脏病 (CKD) 的严重程度不成比例。本研究的目的是在慢性肾脏病儿童 (CKiD) 前瞻性队列研究中,系统比较 ARPKD 患儿与其他先天性 CKD 病因患儿的生长参数。
分析 ARPKD 患儿(n=22)与 2 个匹配对照组(无功能/发育不良/发育不全肾组,n=44;梗阻性尿路组,n=44)的身高标准差评分 (z 评分)、严重矮小症患儿比例 (z 评分 < -1.88)、生长激素使用率和身高 z 评分年变化率。使用 Wilcoxon 秩和检验或 Fisher 确切概率法比较组间基线特征差异,采用 Wilcoxon 符号秩检验比较身高 z 评分年变化率的匹配差异。
ARPKD 患儿的身高 z 评分中位数为-1.1 [四分位距(IQR)-1.5,-0.2];14%的 ARPKD 患儿身高 z 评分 < -1.88,18%的患儿使用生长激素。ARPKD 组与对照组的身高 z 评分中位数、身高 z 评分 < -1.88 的患儿比例、生长激素使用率和身高 z 评分年变化率无显著差异。
在 CKiD 队列中,患有轻度至中度 CKD 的 ARPKD 患儿生长异常的患病率较高,但与其他先天性 CKD 病因患儿相似。本研究不支持 ARPKD 对生长的特异性疾病影响,至少在轻度至中度 CKD 的患儿亚组中是这样。